<DOC>
	<DOCNO>NCT00000680</DOCNO>
	<brief_summary>1 ) To determine whether possible remove culture ( increase number activate ) laboratory , CD8 ( + ) lymphocytes ( white blood cell ) HIV-infected patient receive zidovudine ( AZT ) ; 2 ) To determine toxicity return patient intravenously expand activate autologous cell ( give patient take ) , without give patient recombinant interleukin-2 ( aldesleukin ; IL-2 ) time ; 3 ) To radiolabel ( mark ) CD8 ( + ) lymphocytes Indium 111 , scan patient determine distribution CD8 ( + ) lymphocytes give IL-2 infusion ; 4 ) To determine toxicity IL-2 give time autologous CD8 ( + ) lymphocytes ; 5 ) To measure change immunology subject follow treatment . CD8 ( + ) cell suppressor/killer lymphocyte cell act limit replication virus . It hop reinfusion activate autologous CD8 ( + ) cell patient AIDS help control opportunistic infection cytomegalovirus toxoplasmosis ( two lead cause sickness death AIDS patient ) . This treatment may also stop HIV virus replicating ( reproduce ) AIDS patient . Further activation cell , infuse , may necessary . It hop IL-2 stimulate patient 's immune system AIDS virus along activate CD8 ( + ) cell . Thus , IL-2 give , effect study .</brief_summary>
	<brief_title>A Phase I Study Autologous , Activated CD8 ( + ) Lymphocytes Expanded In Vitro Infused With Without Recombinant Interleukin-2 Patients With AIDS Severe ARC</brief_title>
	<detailed_description>CD8 ( + ) cell suppressor/killer lymphocyte cell act limit replication virus . It hop reinfusion activate autologous CD8 ( + ) cell patient AIDS help control opportunistic infection cytomegalovirus toxoplasmosis ( two lead cause sickness death AIDS patient ) . This treatment may also stop HIV virus replicating ( reproduce ) AIDS patient . Further activation cell , infuse , may necessary . It hop IL-2 stimulate patient 's immune system AIDS virus along activate CD8 ( + ) cell . Thus , IL-2 give , effect study . AMENDED : 09/28/90 The CD8 lymphocytes grown vitro 21 day infusion . Leukapheresis infusion continue every 21 day 3 infusion last infusion week 16 . During week 13 16 , indium 111 radio label cell injected permit determination distribution pharmacokinetics infused cell . At week 16 , IL-2 administer concurrently Indium 111 label cell CD8+ lymphocytes - deliver continuous infusion 5 day follow cell infusion . Patients follow clinic 1 week prior schedule infusion , infusion week every 2 week week 21 week 27 . Original design : Patients undergo leukapheresis every 2 week total 6 time initial phase study . During procedure , catheter place arm vein , blood flow machine separate lymphocytes blood component . The blood return patient 's body catheter . Less 10 percent lymphocyte blood removed process . The CD8 ( + ) cell take patient cultured laboratory increase 10- 1000-fold . These cell infuse back patient take . The first two patient admit 24 hour time infusion . In absence severe side effect , subsequent four patient infused clinic . Patients admit 5 day continuous infusion IL-2 week 13 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Zidovudine ( AZT ) treatment 20 week last infusion unless medically contraindicate . Allowed : Aerosolized pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Oral antibiotic PCP prophylaxis hematologically stable regimen least 30 day prior study entry . Patients must follow : Positive HIV antibody test federally license ELISA . Positive HIV culture plasma p24 antigen . CDC Group IV severe AIDSrelated complex ( ARC ) AIDS . Must zidovudine ( AZT ) least 6 week prior infusion agree continue medication study 20 week last infusion unless medically contraindicate . Allowed : Kaposi 's sarcoma . Exclusion Criteria Coexisting Condition : AMENDED : Pulmonary disease require treatment . AMENDED : Significant central nervous system disease include AIDS dementia , psychiatric disability , seizure disorder . AMENDED : Symptomatic HIV CNS infection symptom compatible HIV encephalopathy . Original design : Patients follow condition symptom exclude : Active bacterial opportunistic infection require treatment . Neoplasms specifically allow , basal cell carcinoma skin , insitu carcinoma cervix . Clinically significant cardiac ( = &gt; class II , New York Heart Association ) peripheral vascular disease require treatment . Hemorrhagic diathesis include hemophilia active bleed disorder . Concurrent Medication : Excluded : Antineoplastic therapy . Medication require treatment active cardiac disease . Cardiac glycoside . Antiarrhythmics . Antianginal agent . Anticoagulants . Thrombolytic agent . Vasodilators . Excluded within 30 day study entry : Antiretroviral agent specifically allow . Corticosteroids . Acyclovir . Excluded within 60 day study entry : Biological response modifier . Patients follow exclude : Unable give properly inform consent reason impaired mentation . Diseases condition specify elsewhere protocol . Required : Zidovudine ( AZT ) least 6 week prior infusion . Risk Behavior : Excluded : Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>T-Lymphocytes , Suppressor-Effector</keyword>
	<keyword>Indium Radioisotopes</keyword>
	<keyword>Leukapheresis</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Immunization , Passive</keyword>
</DOC>